In recent years, the pharmaceutical industry has been rocked by a series of lawsuits alleging severe side effects caused by Mounjaro, a medication designed for Type 2 diabetes management. The legal and medical saga surrounding Mounjaro involves complex legal proceedings and allegations of severe side effects opening up many potential avenues for affected individuals to seek legal recourse.
Written by :
Hristina Nikolovska
Edited by :
Hristina Nikolovska
First Hearing in the Mounjaro MDL
The first hearing of the Mounjaro multidistrict litigation (MDL) on March 14, 2024, marked a significant development in the legal proceedings. Held in Philadelphia, this initial hearing set the stage for how the consolidated cases would be managed and scrutinized.
Consolidation into Multidistrict Litigation
A multidistrict litigation (MDL) is established in the Eastern District of Pennsylvania, consolidating 55 lawsuits involving Mounjaro and other GLP-1 RA class drugs. This consolidation underscores the scale of the legal challenges facing these medications and indicates a coordinated approach to managing the numerous claims related to their side effects.
Mounjaro Lawsuit Filed in Louisiana
On December 22, 2023, a significant legal action commenced with the filing of a lawsuit against pharmaceutical giants Novo Nordisk and Eli Lilly in Louisiana. This case, representing one of the early formal complaints, highlighted severe health complications allegedly linked to Mounjaro and Ozempic, including symptoms like extreme vomiting and tooth loss.
Court Denies Dismissal Motion
A judge allows Jaclyn Bjorklund’s lawsuit to proceed against Novo Nordisk and Eli Lilly, denying the motion to dismiss the case. This legal development is significant as it confirms the court's willingness to hear cases related to Mounjaro and similar drugs, setting a precedent for future litigation.
Counterfeit Mounjaro Legal Actions
Eli Lilly undertakes legal action against compounding pharmacies, medspas, and wellness centers, alleging the fraudulent distribution of counterfeit products labeled as Mounjaro. This case adds complexity to the legal landscape surrounding the drug, highlighting issues of market integrity and consumer safety.
First Gastroparesis Lawsuit Filed
Morgan & Morgan files the first known lawsuit against Eli Lilly, alleging that Mounjaro caused severe gastroparesis in their client. This marks the beginning of legal scrutiny over Mounjaro's safety and the adequacy of warnings provided to patients.
FDA Approval and Risk Acknowledgment
The U.S. Food and Drug Administration (FDA) approves Eli Lilly’s Mounjaro for controlling blood sugar in Type 2 diabetes patients. This approval notes the potential for gastrointestinal side effects, a factor that would later become central to legal claims, indicating early awareness of the risks associated with the drug.
Mounjaro, a medication approved by the FDA in May 2022, is primarily used for treating Type 2 diabetes. Its active ingredient, tirzepatide, aids in blood sugar control and weight loss.
Despite its medical benefits, Mounjaro has been at the center of legal controversies due to allegations of causing severe gastrointestinal side effects like gastroparesis, also known as stomach paralysis.
The unfolding legal narrative around Mounjaro spotlights the complex interplay between pharmaceutical innovation, patient safety, and corporate accountability.
Lawsuits against Mounjaro began to surface shortly after its FDA approval in May 2022, with the first notable case filed in August 2023. The legal actions have been mounting over time, as more patients report severe symptoms after using the drug, indicating a trend that continues to the present with an increase in filed lawsuits.
Allegations in the Mounjaro stomach paralysis lawsuit center on the severe side effects caused by the drug, specifically gastroparesis. This condition significantly impairs quality of life, leading to symptoms like severe vomiting, nausea, abdominal pain, and bloating.
Plaintiffs argue that Eli Lilly failed to provide adequate warnings based on reports and studies linking Mounjaro to these severe gastrointestinal issues. The core of their argument hinges on the premise that, despite evidence and patient experiences indicating a risk of gastroparesis, the company did not sufficiently communicate these dangers to patients and healthcare professionals.
This gap between known risks and communicated warnings forms the crux of the legal battle, with plaintiffs often relying on their adverse experiences and emerging medical research to support their claims.
As mentioned above, the legal battle against Mounjaro began in August 2023 when the first lawsuit was filed, marking a critical point in the scrutiny of the drug's side effects.
Namely, a Louisiana resident experienced severe health issues, leading to the initiation of legal action. This individual suffered from extreme symptoms of gastroparesis, a debilitating condition characterized by delayed gastric emptying, which resulted in severe vomiting, abdominal pain, and nutritional deficiencies.
These adverse effects significantly impacted the plaintiff's quality of life, prompting the lawsuit against Eli Lilly for allegedly failing to warn about the risks of such severe side effects.
This case has drawn attention to the potential health risks associated with Mounjaro and has become a focal point for other similar legal claims. The lawsuit's outcome is anticipated to set a precedent for how future cases related to Mounjaro's side effects are handled legally.
At the center of a growing legal maelstrom is Eli Lilly, the pharmaceutical giant behind Mounjaro, facing the legal consequences of numerous product liability lawsuits.
These legal actions have converged on the company’s doorstep, accusing it of not adequately warning about the drug’s potential to cause serious gastrointestinal issues, including gastroparesis.
Eli Lilly is now navigating a thicket of litigation, as plaintiffs argue that the company’s disclosures about the risks were insufficient. This situation spotlights the manufacturer's responsibility to ensure patient safety, raising critical questions about Mounjaro's regulatory approval process and post-marketing surveillance practices.
The outcome of these lawsuits could have far-reaching implications for Eli Lilly and the pharmaceutical industry at large, emphasizing the importance of transparent and comprehensive communication of potential drug risks.
Recent scientific studies have heightened concerns regarding the use of Mounjaro and other GLP-1 receptor agonist (RA) medications, drawing attention to their potential severe side effects.
A study published in the October edition of the JAMA Network, a peer-reviewed medical journal, utilized data from the PharMetrics Plus database, analyzing prescription records from 16 million patients between 2006 and 2020. [1]
This comprehensive study found an increased risk of pancreatitis, gastroparesis, and bowel obstruction in users of semaglutide, a key ingredient in Mounjaro and similar drugs.
The research aimed to deepen understanding of the connection between semaglutide use and gastrointestinal complications, particularly for those considering these drugs for weight loss.
The emerging concerns regarding GLP-1 receptor agonist drugs like Mounjaro have been further substantiated by two other recent studies.
A study published by the BMJ highlighted that patients using these medications for weight loss were more likely to encounter gastrointestinal issues, with a correlation between higher doses of these drugs and an increased risk of symptoms such as nausea, vomiting, and gastroparesis, also known as stomach paralysis. [2]
Notably, Mounjaro was identified as the most potent among these medications, raising significant safety questions.
In addition, a study from Frontiers Journal presented alarming findings that link the use of GLP-1 medications to adverse psychiatric events, expanding the spectrum of potential side effects. [3]
These studies contribute to the growing body of evidence that, while these drugs are effective for diabetes and weight loss, they carry risks that need further investigation to fully understand their impact on patients' health.
Recent studies have linked Mounjaro to serious gastrointestinal issues. If you or a loved one are experiencing such side effects, you may be entitled to compensation.
See if you have a caseGastroparesis, commonly referred to as stomach paralysis, is a chronic condition that affects the normal spontaneous movement of the stomach muscles, leading to delayed emptying of stomach contents into the small intestine.
This condition is particularly concerning in the context of medications like Mounjaro, which are part of the GLP-1 receptor agonist (RA) class, as they are known to impact gastric motility.
Characteristically, gastroparesis disrupts the stomach's ability to crush food and move it into the small intestine in a regular, controlled manner. Symptoms can be debilitating and vary in severity, including nausea, vomiting, early satiety (feeling full quickly after eating), abdominal bloating, and persistent abdominal pain.
In more severe cases, it can lead to nutritional deficiencies, unintended weight loss, and fluctuations in blood glucose levels due to the unpredictable digestion and absorption of food.
GLP-1 receptor agonist (RA) medications are a class of drugs used to treat type 2 diabetes and obesity. These medications work by mimicking the effects of the glucagon-like peptide-1 hormone, which stimulates insulin secretion, inhibits glucagon release, and slows gastric emptying, helping to control blood sugar levels and promote weight loss.
Some of the GLP-1 RAs that have been associated with several adverse medical events, besides gastroparesis, include:
Patients taking these medications are advised to monitor for symptoms and communicate regularly with their healthcare providers. The link between GLP-1 RAs and gastroparesis is particularly concerning, as it can significantly affect a patient's quality of life and requires careful management.
Ongoing research continues to explore the full spectrum of side effects to better understand the risk profile of these drugs and inform safer use.
The legal landscape surrounding the use of GLP-1 receptor agonist drugs like Mounjaro has become a battleground for significant litigation challenges, with pharmaceutical giants Novo Nordisk and Eli Lilly at the center.
In response to the lawsuits, both Novo Nordisk and Eli Lilly have attempted to dismiss the claims, arguing against the legal grounds of the accusations.
For instance, in the case brought by Louisiana resident Jaclyn Bjorklund, who experienced severe health issues allegedly due to these medications, Novo Nordisk tried to dismiss the lawsuit on jurisdictional grounds and questioned the connection between the company's actions and the state of Louisiana.
Meanwhile, Eli Lilly has also been actively defending its position, contesting the adequacy of the plaintiff's claims and the evidence presented.
These companies are not just fighting individual cases but are also facing the potential consolidation of lawsuits into multidistrict litigation (MDL), which could unify numerous claims under one jurisdiction, thereby streamlining the legal process but also increasing the stakes of the litigation.
The outcome of these legal strategies and challenges is closely watched, as it will influence the course of current and future litigation related to the safety and marketing of GLP-1 RA medications.
Navigating the complex terrain of pharmaceutical litigation requires understanding who is eligible to file claims and how legal representation can be secured.
To be eligible to file a claim for stomach paralysis allegedly caused by Mounjaro, individuals must typically demonstrate that they were prescribed and took Mounjaro and subsequently developed gastroparesis or similar severe gastrointestinal symptoms.
Documentation such as medical records, doctor’s notes, and pharmacy records proving the use of Mounjaro and linking it to the health complications experienced is essential in these cases.
Additionally, claimants in Mounjaro stomach paralysis lawsuits must demonstrate the impact of the condition on their daily life and well-being. This includes detailing the severity of the symptoms, the duration of the suffering, and the extent of medical treatments required to manage the condition.
Finally, the statute of limitations is another important aspect claimants must consider. This legal timeframe dictates how long after the occurrence of an injury or the discovery of that injury a claimant has to file a lawsuit. The specific period can vary by state or jurisdiction and may depend on when the harm was identified or should have been recognized.
For this reason, potential claimants should not waste any time and seek legal consultation as soon as they suspect that their health issues may be linked to the use of Mounjaro.
If you're grappling with stomach paralysis potentially linked to Mounjaro, Legal.com can guide you toward the legal expertise you need. In our directory, you will find the ideal legal representation to assist you in your pursuit of justice.
Each of the attorneys showcased on our platform are selected for their:
What’s more, the attorneys listed on Legal.com are known for their tireless work ethic, dedicated to securing the compensation you rightfully deserve. They provide a comprehensive suite of services, including:
Gastroparesis linked to Mounjaro typically includes symptoms such as severe vomiting, nausea, abdominal pain, bloating, feeling full quickly after eating, and sometimes malnutrition due to the impaired digestive process.
Patients who believe they have suffered from gastroparesis or other severe side effects due to Mounjaro should consult with a lawyer specializing in pharmaceutical litigation. The lawyer will evaluate their case, gather necessary medical evidence, and file a claim on their behalf.
Affected patients can expect compensation that covers medical expenses, lost wages, pain and suffering, and potentially punitive damages if negligence is proven. The exact amount depends on the severity of the symptoms, the impact on the individual’s life, and the specific details of the case.
Submit your inquiry through our contact form to start your search for legal assistance. Our directory connects you with experienced lawyers in a variety of practice areas, ensuring you have access to advice when you need it most.
Don’t have an account? Sign up
Defective Medical Device Lawsuits 
Product Liability Lawsuits 
Sign up using your Google account
Sign up using your LinkedIn account